By Denny Jacob
Arvinas shares dived 40% following results from a Phase 3 clinical trial evaluating vepdegestrant as a treatment for a type of metastatic breast cancer.
Shares were trading around $10.35. The stock is down 61% over the last year.
The biopharmaceutical company in conjunction with Pfizer said the trial did not reach statistical significance in improvement in progression-free survival in the intent-to-treat population.
The trial, however, did meet its primary endpoint in the estrogen receptor 1-mutual population, which the company said demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant.
The two companies in July 2021 announced plans to collaborate on the co-development and co-commercialization of vepdegestrant.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 11, 2025 08:37 ET (12:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.